IPM Take
A diagnosis is not a risk score.
For people with epilepsy, the barrier to work can persist long after seizures are controlled. The Federal Motor Carrier Safety Administration notice does not change the law, nor does it approve anyone automatically. But it tests an important principle: where an individual has a stable clinical record, sustained seizure freedom and specialist support, should a diagnosis alone remain the final answer?
Public safety is non-negotiable. So is the need for policy that distinguishes evidence-based risk from blanket exclusion.
Executive Summary
The U.S. Federal Motor Carrier Safety Administration has published a notice of applications from 16 individuals seeking exemptions from the federal restriction on interstate commercial driving for people with epilepsy or other conditions likely to cause loss of consciousness or loss of vehicle control.
If granted, the exemptions would permit these applicants, who have experienced one or more seizures and take antiseizure medication, to operate commercial motor vehicles in interstate commerce. The agency will review each application individually, considering medical information, driving records, safety analyses and public comments.
This is not a policy change and does not create an automatic right to drive commercially. Under federal law, FMCSA must determine whether granting an exemption would be likely to achieve a level of safety equivalent to, or greater than, the level achieved without it.
Why it matters
- Patients / advocates: Epilepsy can affect work, income, independence and identity long after seizures are stabilised.
- Regulators: Case-by-case assessment can avoid blanket exclusion, but it needs transparent criteria, consistent decision-making and a credible safety threshold.
- Policymakers: Employment and mobility are neurological access issues. A care pathway is incomplete if it ignores the life someone can return to after clinical stability.
A seizure can change a life in seconds.
Policy can make that change permanent.
For many people with epilepsy, the challenge is not only achieving seizure control. It is living with the social and economic consequences of a diagnosis long after the clinical picture has stabilised. Driving restrictions can determine whether someone keeps a job, changes career, supports a family or remains financially independent.
Commercial driving carries real public-safety responsibilities. No serious policy should pretend otherwise. A seizure behind the wheel of a commercial vehicle can have catastrophic consequences.
But the existence of risk does not justify treating every person with epilepsy as the same risk forever.
The new FMCSA notice concerns 16 individual exemption applications. Each applicant is being assessed separately. The agency will review medical information, driving history, safety analyses and public comments before deciding whether an exemption can meet the required safety standard.
That is the right frame.
The applicants include people who have been seizure-free for years, including individuals with stable antiseizure treatment and physician support. This does not mean that exemptions will be granted. It does mean the system is being asked to look at evidence about the person, rather than stopping at the diagnosis.
The policy issue reaches beyond commercial vehicles.
Epilepsy care is often measured through seizure frequency, medication tolerance and clinic follow-up. Those matter. But people live with epilepsy through work, transport, stigma, financial insecurity and the constant calculation of what they may lose if a seizure returns.
That is why this notice belongs in a precision-medicine conversation.
Personalised care should not end when the prescription is written. It should extend to whether systems recognise stable disease, individual risk and the possibility of participation in work and public life.
The goal is not lower safety standards. The goal is better standards, ones strict enough to protect the public and precise enough to avoid turning a diagnosis into a lifelong employment sentence.
